Kidney International Reports最新文献

{"title":"Association of Pulmonary Hypertension With Outcomes in Kidney Transplant Recipients","authors":"Isabel G. Scalia ,&nbsp;Juan M. Farina ,&nbsp;Milagros Pereyra Pietri ,&nbsp;Nima Baba Ali ,&nbsp;Mohammed Tiseer Abbas ,&nbsp;Kamal Awad ,&nbsp;Ahmed K. Mahmoud ,&nbsp;Niloofar Javadi ,&nbsp;Nadera N. Bismee ,&nbsp;Samy Riad ,&nbsp;Hani Wadei ,&nbsp;Byron Smith ,&nbsp;D. Eric Steidley ,&nbsp;Timothy Barry ,&nbsp;Robert L. Scott ,&nbsp;Yeoungjee Cho ,&nbsp;David W. Johnson ,&nbsp;Chadi Ayoub ,&nbsp;Reza Arsanjani ,&nbsp;Girish Mour","doi":"10.1016/j.ekir.2025.04.058","DOIUrl":"10.1016/j.ekir.2025.04.058","url":null,"abstract":"<div><h3>Introduction</h3><div>Pulmonary hypertension (PHTN) in patients with kidney failure is known to be associated with increased morbidity and mortality. Despite this, there is a relative paucity of large cohort data regarding its clinical impact following kidney transplantation (KTx). Therefore, this study sought to directly evaluate the prognostic implications of pretransplant PHTN in one of the largest kidney transplant cohorts to date.</div></div><div><h3>Methods</h3><div>This retrospective observational cohort analysis reviewed all consecutive kidney transplant recipients at three tertiary transplant centers in the United States between January 1, 2011 and September 30, 2021. Pretransplant PHTN was defined as right ventricular systolic pressure (RVSP) ≥ 35 mm Hg on transthoracic echocardiography (TTE). Clinical outcomes were compared between patients with and without pretransplant PHTN, including mortality and allograft failure (overall and censored by mortality).</div></div><div><h3>Results</h3><div>A total of 5322 KTx recipients were included; mean age 55.2 ± 13.7 years, 58.8% male. Of these patients, 1726 (32.4%) had pretransplant PHTN. PHTN was independently associated with significantly poorer outcomes: mortality (adjusted hazard ratio [aHR]: 1.24, 95% confidence interval [CI]: 1.06–1.45, <em>P</em> = 0.007), overall allograft failure (aHR 1.24, 95% CI: 1.09–1.42, <em>P</em> = 0.002), and death-censored allograft loss (aHR: 1.25, 95% CI: 1.01–1.56, <em>P</em> = 0.044). Risk of mortality and overall allograft failure also appeared to be incrementally higher with increasing pulmonary pressures.</div></div><div><h3>Conclusion</h3><div>Pretransplant PHTN classified by echocardiographic RVSP was independently and incrementally associated with an increased risk of mortality and allograft failure post-KTx. In pretransplant work up, this may allow for identification of a high-risk cohort that could benefit from further evaluation, early intervention, and closer surveillance in the posttransplant period.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 7","pages":"Pages 2394-2404"},"PeriodicalIF":5.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complement Proteins Identify Rapidly Progressive Diabetic Kidney Disease","authors":"Donghwan Yun ,&nbsp;Sohyun Bae ,&nbsp;Yuqian Gao ,&nbsp;Lauren Lopez ,&nbsp;Dohyun Han ,&nbsp;Carrie D. Nicora ,&nbsp;Tae Youn Kim ,&nbsp;Kyung Chul Moon ,&nbsp;Dong Ki Kim ,&nbsp;Thomas L. Fillmore ,&nbsp;Yon Su Kim ,&nbsp;Avi Z. Rosenberg ,&nbsp;Weijie Wang ,&nbsp;Pinaki Sarder ,&nbsp;Wei-Jun Qian ,&nbsp;Maryam Afkarian ,&nbsp;Seung Seok Han","doi":"10.1016/j.ekir.2025.04.061","DOIUrl":"10.1016/j.ekir.2025.04.061","url":null,"abstract":"<div><h3>Introduction</h3><div>Mechanisms underlying diabetic kidney disease (DKD) progression remain incompletely understood. This study used untargeted and targeted mass spectrometry-based proteomics in 2 independent cohorts to capture rapidly progressive DKD.</div></div><div><h3>Methods</h3><div>We conducted untargeted and targeted mass spectrometry on urine samples from Korean patients with type 2 diabetes and biopsy-confirmed diabetic nephropathy (SNUH-DN cohort; <em>n</em> = 64) and a DKD subgroup of the Chronic Renal Insufficiency Cohort (CRIC-T2D; <em>n</em> = 282), respectively. Urine proteins associated with kidney disease progression (doubling of serum creatinine, ≥ 50% decrease in estimated glomerular filtration rates [eGFRs], or progression to end-stage kidney disease[ESKD]) were identified after adjusting for eGFR, proteinuria, and other clinical variables.</div></div><div><h3>Results</h3><div>In the SNUH-DN patients, urine proteins clustered into 2 groups, with cluster 1 exhibiting a 4.6-fold higher hazard of disease progression (95% confidence interval [CI]: 1.9–11.5) than cluster 0. Proteins in cluster 1 mapped to 10 pathways, 4 of the top 5 being complement-related. A high complement score, derived from urine complement protein abundance, correlated with histopathologic features of DKD and conferred a 2.4-fold greater hazard of disease progression (95% CI: 1.0–5.4) than a low complement score. In CRIC-T2D, targeted mass spectrometry similarly confirmed that complement score stratified patients into rapid and slow DKD progression groups. In both cohorts, complement score exhibited a linear association with disease progression.</div></div><div><h3>Conclusion</h3><div>The strong association between complement activation and rapid DKD progression highlights the need to explore complement inhibition as a potential therapeutic strategy for DKD.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 7","pages":"Pages 2296-2310"},"PeriodicalIF":5.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Dried Blood Spot Sampling for Monitoring Children With Immune-Mediated Glomerulopathies and After Kidney Transplantation” [Kidney International Reports Volume 9, Issue 11, November 2024, Pages 3236-3249]","authors":"Lena Brunkhorst ,&nbsp;Michael Terhardt ,&nbsp;Björn Bulitta ,&nbsp;Miriam Gutting ,&nbsp;Nils Janzen ,&nbsp;Dieter Haffner ,&nbsp;Nele Kanzelmeyer","doi":"10.1016/j.ekir.2025.05.002","DOIUrl":"10.1016/j.ekir.2025.05.002","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 7","pages":"Pages 2494-2495"},"PeriodicalIF":5.7,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Genotype-Phenotype Correlations in Denys-Drash Syndrome in Children” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1205-1212]","authors":"Mathilde Glénisson ,&nbsp;Mathilde Grapin ,&nbsp;Thomas Blanc ,&nbsp;Evgenia Preka ,&nbsp;Julien Hogan ,&nbsp;Manon Aurelle ,&nbsp;Gwenaëlle Roussey ,&nbsp;Antoine Mouche ,&nbsp;Caroline Rousset-Rouviere ,&nbsp;Robert Novo ,&nbsp;Camille Faudeux ,&nbsp;Marc Fila ,&nbsp;Isabelle Vrillon ,&nbsp;Sylvie Cloarec ,&nbsp;Thomas Simon ,&nbsp;Jérôme Harambat ,&nbsp;Edouard Martinez Casado ,&nbsp;Julien Rod ,&nbsp;Morgane Carre Lecoindre ,&nbsp;Laetitia Martinerie ,&nbsp;Sabine Sarnacki","doi":"10.1016/j.ekir.2025.05.001","DOIUrl":"10.1016/j.ekir.2025.05.001","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 7","pages":"Page 2494"},"PeriodicalIF":5.7,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Furosemide and Serum Protein-Bound Uremic Toxin Concentrations in Patients With CKD","authors":"Margaux Costes-Albrespic ,&nbsp;Natalia Alencar de Pinho ,&nbsp;Islam Amine Larabi ,&nbsp;Carolla El Chamieh ,&nbsp;Solène M. Laville ,&nbsp;Denis Fouque ,&nbsp;Maurice Laville ,&nbsp;Luc Frimat ,&nbsp;Jean-Claude Alvarez ,&nbsp;Ziad A. Massy ,&nbsp;Sophie Liabeuf","doi":"10.1016/j.ekir.2025.04.040","DOIUrl":"10.1016/j.ekir.2025.04.040","url":null,"abstract":"<div><h3>Introduction</h3><div>Furosemide is commonly prescribed to patients with chronic kidney disease (CKD) but may impair the kidney’s excretion of protein-bound uremic toxins (PBUTs) via the organic anion transporters 1 and 3 (OAT1 and OAT3). We evaluated the association between furosemide prescription (status and dose level) and the serum concentrations of free OAT1/3-inhibiting uremic toxins (UTs) in patients with CKD.</div></div><div><h3>Methods</h3><div>We included 2342 patients with CKD (stages 2–5) from the CKD–Renal Epidemiology and Information Network (CKD-REIN) cohort and with centralized serum UT assay data at baseline. The UTs were assayed using liquid chromatography - tandem mass spectrometry. The OAT1/3-inhibiting UTs identified in a literature review included indoxyl sulphate (IS), kynurenine (Kyn), p-cresyl sulphate (PCS), and indole-3-acetic acid (IAA). Multiple linear regression was used to assess each PBUT or their sum (<span><math><mrow><mi>Σ</mi><mtext>UTs</mtext></mrow></math></span> _free) as the dependent variable.</div></div><div><h3>Results</h3><div>Patients prescribed furosemide (<em>n</em> = 799, 34%) were older and had a lower estimated glomerular filtration rate (eGFR), a higher C-reactive protein (CRP) concentration, more comorbidities, and more concomitant medications than patients not prescribed furosemide. After adjustment for potential confounders, patients prescribed &gt; 120 mg furosemide had significantly higher serum concentrations of <span><math><mrow><mi>Σ</mi><mtext>UTs</mtext></mrow></math></span> _free (+19.1%), IS (+31.9%), Kyn (+9.3%), PCS (+29.3%), and IAA (+162.9%) than patients not prescribed furosemide. Using a smooth function to model the association between the furosemide dose level and PBUTs, we observed (for <span><math><mrow><mi>Σ</mi><mtext>UTs</mtext></mrow></math></span> _free and each free UT) a steep increase between 80 and 100 mg and then a high plateau.</div></div><div><h3>Conclusion</h3><div>In patients with CKD, furosemide (particularly at a dose level &gt; 120 mg) is independently associated with higher serum free PBUT concentrations. Our findings suggest that drug-UT competition contributes to PBUT accumulation.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 7","pages":"Pages 2165-2177"},"PeriodicalIF":5.7,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab-Associated Crescentic Glomerulonephritis With IgA Vasculitis-Like Features","authors":"Tao Zhao ,&nbsp;Xin Zhang ,&nbsp;Yang Li ,&nbsp;Tao Su","doi":"10.1016/j.ekir.2025.04.052","DOIUrl":"10.1016/j.ekir.2025.04.052","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 7","pages":"Pages 2489-2490"},"PeriodicalIF":5.7,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Determination of Tacrolimus Concentration–Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation","authors":"Christophe Masset ,&nbsp;Marine Lorent ,&nbsp;Clarisse Kerleau ,&nbsp;Claire Garandeau ,&nbsp;Aurélie Houzet ,&nbsp;Simon Ville ,&nbsp;Diego Cantarovich ,&nbsp;Gilles Blancho ,&nbsp;Magali Giral ,&nbsp;Jacques Dantal","doi":"10.1016/j.ekir.2025.02.014","DOIUrl":"10.1016/j.ekir.2025.02.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Fast tacrolimus–metabolizing kidney transplant recipients (KTRs) (i.e., tacrolimus trough-level/total daily dose [C0/D &lt; 1.05]) have poorer allograft function; however, their identification in a real-life setting is challenging. We investigated the reproducibility of tacrolimus metabolic status during the first months after transplantation and its association with long-term allograft outcomes.</div></div><div><h3>Methods</h3><div>All KTRs between 2000 and 2019 with a functional allograft at 1 month and receiving tacrolimus in our center were included. Fast or slow tacrolimus metabolizers were classified according to the time spent with a C0/D &lt; 1.05 (&gt; 75% = High, &lt; 25% = Low) at various time points posttransplantation. We first determined the earliest accurate time for patient categorization by investigating C0/D variability during the first months. Second, a multivariate cause-specific Cox model studying allograft outcomes was performed in groups identified by their status determined from the earliest accurate timepoint after transplantation.</div></div><div><h3>Results</h3><div>Among 1979 patients included in the analysis, 2 months was the earliest accurate timepoint to determine High patients (85% of High patients identified at 2 months remained High long-term, Brier score = 0.06). Multivariate analysis revealed that High patients determined at 2 months (<em>n</em> = 499) had a significantly higher risk of allograft loss (cause-specific hazard ratio [CS-HR] = 2.00, 95% confidence interval [CI] = 1.48–2.69) and allograft rejection (CS-HR = 1.71, 95% CI = 1.15–2.54) than Low patients after adjustment for confounding factors. Moreover, allograft function was lower in High patients (46.7 vs. 52.9 ml/min, at 3 years, <em>P</em> &lt; 0.0001) with a higher proportion of chronic vascular lesions at 1 year.</div></div><div><h3>Conclusion</h3><div>C0/D is a simple and pragmatic tool capable of identifying patients at risk of rejection and allograft failure as early as the second month posttransplantation.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1428-1440"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Nephrology Education with POCUS: Key Insights From the American Society of Nephrology Kidney Week 2024 Precourse","authors":"Abhilash Koratala ,&nbsp;Nathaniel Reisinger","doi":"10.1016/j.ekir.2025.03.039","DOIUrl":"10.1016/j.ekir.2025.03.039","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1309-1312"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating Novel Biomarkers in Definitions of Drug-Induced Acute Kidney Injury","authors":"Boon Wee Teo ,&nbsp;Chirag R. Parikh","doi":"10.1016/j.ekir.2025.03.013","DOIUrl":"10.1016/j.ekir.2025.03.013","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1313-1314"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants","authors":"Zohreh Gholizadeh Ghozloujeh ,&nbsp;Richard J. Glassock ,&nbsp;Ayman Al Jurdi ,&nbsp;Kenar D. Jhaveri ,&nbsp;Giv Heidari-Bateni ,&nbsp;Divya Bajpai ,&nbsp;Edgar Lerma ,&nbsp;Junnan Wu ,&nbsp;Amir Abdipour ,&nbsp;Sayna Norouzi","doi":"10.1016/j.ekir.2025.02.010","DOIUrl":"10.1016/j.ekir.2025.02.010","url":null,"abstract":"<div><div>Nephrotic syndrome (NS) is associated with a significantly elevated risk of venous thromboembolic events (VTEs), which contribute to morbidity and mortality. Current guidelines for VTE prophylaxis in patients with NS are based on limited evidence, primarily from observational studies. This review describes the complexities of hypercoagulability in NS, with a focus on aspirin as a potential prophylactic agent. We outline the pathophysiology underlying VTE in NS, highlighting factors such as hypoalbuminemia, anticoagulant loss, and heightened platelet reactivity. This review also summarizes the available data on the role of aspirin in reducing thromboembolic risk. Although aspirin may benefit select patient groups, its efficacy remains inconclusive, with some studies suggesting a combination of aspirin and anticoagulants for more effective risk reduction. Future studies, particularly large-scale randomized controlled trials (RCTs), are necessary to clarify the role of aspirin in preventing VTEs in this population. Our review underscores the need for individualized prophylactic strategies that balance thrombotic and bleeding risks in patients with NS.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1335-1345"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}